Anixa Biosciences

ANIXPhase 1

San Jose, United StatesFounded 1989anixa.com

Anixa Biosciences is advancing a dual-platform approach to oncology, combining a next-generation CAR-T variant (CER-T) for cancer treatment with a novel vaccine platform targeting 'retired' tissue-specific proteins for cancer prevention. The company's most advanced programs are a breast cancer vaccine for triple-negative breast cancer (TNBC) and an ovarian cancer vaccine, both leveraging its proprietary vaccine technology. Led by a seasoned management team with deep experience in biotech and supported by a world-class scientific advisory board, Anixa is positioned to address significant unmet needs across multiple high-incidence cancers.

Market Cap

$864.4M

Founded

1989

Focus

BiologicsDiagnosticsCell & Gene Therapy

ANIX · Stock Price

USD 25.7896.09 (-78.85%)

Historical price data

AI Company Overview

Technology Platform

Two core platforms: 1) A novel Chimeric Endocrine Receptor T-cell (CER-T) immunotherapy, a variant of CAR-T, and 2) A 'retired tissue-specific protein' vaccine platform that targets proteins expressed only during specific developmental stages and re-expressed in certain cancers.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage	Watch
Follicle Stimulating Hormone Receptor T Cells	Ovarian Cancer	Phase 1
α-lactalbumin vaccine + Zymosan	Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer	Phase 1

Opportunities

Validating the 'retired protein' vaccine platform in Phase 1 breast cancer trials could unlock a pipeline targeting multiple high-incidence cancers (ovarian, lung, colon, prostate).

The novel CER-T technology offers a differentiated entry into the large and growing cell therapy market.

Successful proof-of-concept may attract major pharma partnerships for co-development and commercialization.

Risk Factors

High clinical development risk as all programs are early-stage with unproven novel platforms.

As a pre-revenue company, it faces significant financial risk and dependence on capital markets, leading to potential shareholder dilution.

Intense competition in immuno-oncology from larger, better-funded entities poses a threat to market entry and timing.

Competitive Landscape

Competes in cancer vaccines against companies developing neoantigen/shared antigen approaches (e.g., BioNTech, Moderna, Gritstone) but differentiates via its 'retired protein' target strategy. In cell therapy, faces giants like Novartis and Gilead, but its CER-T platform aims for a safer, more specific profile. Its preventive oncology focus is a less crowded, pioneering niche.